Vanda Pharmaceuticals Inc. (VNDA) P/E Ratio History
Deep ValueTrading at -1.6x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2010–2023
Loading P/E history...
P/E Ratio Analysis
As of June 29, 2026, Vanda Pharmaceuticals Inc. (VNDA) trades at a price-to-earnings ratio of -1.6x, with a stock price of $6.01 and trailing twelve-month earnings per share of $-4.03.
The current P/E is 105% below its 5-year average of 34.4x. Over the past five years, VNDA's P/E has ranged from a low of 4.8x to a high of 96.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, VNDA trades at a 107% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, VNDA trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VNDA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
VNDA Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
VNDA P/E vs Peers
Neuroscience and Psychiatry Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 10.9 | - | +264% | |
| $4B | 11.1 | - | +68% | |
| $2B | 7.1Lowest | 0.69 | +817%Best | |
| $993M | 157.8 | - | +107% | |
| $9B | 29.3 | 1.27 | -25% | |
| $2B | 72.6 | - | +194% | |
| $2B | 9.7 | 0.06Best | +40% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
VNDA Historical P/E Data (2010–2023)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q4 | Dec 31 2023 | $4.22 | $0.04 | 96.6x | -7% |
| FY2023 Q3 | Sep 30 2023 | $4.32 | $0.21 | 21.0x | -80% |
| FY2023 Q2 | Jun 30 2023 | $6.59 | $0.26 | 25.3x | -76% |
| FY2023 Q1 | Mar 31 2023 | $6.79 | $0.28 | 24.3x | -77% |
| FY2022 Q4 | Dec 31 2022 | $7.39 | $0.11 | 65.6x | -37% |
| FY2022 Q3 | Sep 30 2022 | $9.88 | $0.11 | 87.7x | -16% |
| FY2022 Q2 | - | $10.90 | $0.20 | 55.8x | -47% |
| FY2022 Q1 | - | $11.31 | $0.32 | 35.3x | -66% |
| FY2021 Q4 | Dec 31 2021 | $15.69 | $0.58 | 27.1x | -74% |
| FY2021 Q3 | - | $17.14 | $0.60 | 28.6x | -73% |
| FY2021 Q2 | Jun 30 2021 | $21.51 | $0.57 | 37.7x | -64% |
| FY2021 Q1 | Mar 31 2021 | $15.02 | $0.56 | 26.8x | -74% |
| FY2020 Q4 | - | $13.14 | $0.42 | 31.3x | -70% |
| FY2020 Q3 | Sep 30 2020 | $9.66 | $0.36 | 26.8x | -74% |
| FY2020 Q2 | - | $11.44 | $2.09 | 5.5x | -95% |
| FY2020 Q1 | - | $10.36 | $2.14 | 4.8x | -95% |
| FY2019 Q4 | - | $16.41 | $2.12 | 7.7x | -93% |
| FY2019 Q3 | Sep 30 2019 | $13.28 | $2.23 | 6.0x | -94% |
| FY2019 Q2 | Jun 30 2019 | $14.09 | $0.52 | 27.2x | -74% |
| FY2019 Q1 | Mar 31 2019 | $18.40 | $0.40 | 46.2x | -56% |
| FY2018 Q4 | Dec 31 2018 | $26.13 | $0.47 | 55.6x | -47% |
| FY2018 Q3 | Sep 30 2018 | $22.95 | $0.24 | 96.0x | -8% |
| FY2018 Q2 | Jun 30 2018 | $19.05 | $0.01 | 2093.4x | +1906% |
| FY2015 Q3 | Sep 30 2015 | $11.28 | $1.18 | 9.6x | -91% |
| FY2015 Q2 | - | $12.69 | $1.36 | 9.3x | -91% |
| FY2015 Q1 | - | $9.30 | $0.85 | 11.0x | -89% |
| FY2014 Q4 | Dec 31 2014 | $14.32 | $0.30 | 48.1x | -54% |
| FY2011 Q2 | - | $7.14 | $0.14 | 49.9x | -52% |
| FY2011 Q1 | - | $7.29 | $0.23 | 31.6x | -70% |
| FY2010 Q4 | Dec 31 2010 | $9.46 | $0.25 | 38.5x | -63% |
Average P/E for displayed period: 104.3x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
16+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
VNDA — Frequently Asked Questions
Quick answers to the most common questions about buying VNDA stock.
What is VNDA's P/E ratio?
Vanda Pharmaceuticals Inc. (VNDA) trailing twelve-month P/E ratio is -1.6x, based on TTM diluted EPS of $-4.03. The 5-year average P/E is 34.4x and the historical range spans 4.8x to 96.6x.
Is VNDA stock overvalued or undervalued?
VNDA trades at -1.6x P/E, below its 5-year average of 34.4x. At the 0th percentile of its historical range (4.8x–96.6x), the stock is priced at a discount to its own history.
Is VNDA stock expensive?
No, VNDA is not expensive on a historical basis. The current P/E of -1.6x is below the 5-year average of 34.4x and sits at the 0th percentile of its valuation range.
What is VNDA's historical P/E range?
Over the past 5 years, VNDA's P/E ratio has ranged from 4.8x to 96.6x, with a median of 27.2x and an average of 34.4x. The current P/E of -1.6x places the stock at the 0th percentile of this range. Full historical data spans 2010–2023.
How does VNDA's P/E compare to the S&P 500?
VNDA trades at -1.6x P/E versus the S&P 500 median of 25.3x. The 106% discount to the market suggests lower growth expectations or perceived higher risk.
How does VNDA's valuation compare to Healthcare peers?
Vanda Pharmaceuticals Inc. P/E of -1.6x compares to the Healthcare sector median of 23.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is VNDA's PEG ratio?
VNDA PEG ratio is N/A, based on a P/E of -1.6x and EPS growth of -1068.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is VNDA's earnings yield?
VNDA earnings yield is N/A, the inverse of its -1.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.